Company Overview

Evotec SE is a Germany-based biotechnology company focused on drug discovery, preclinical development, and advanced biologics manufacturing services for pharmaceutical, biotechnology, and academic partners. The company operates across the life sciences and contract research industries, combining proprietary research platforms with collaborative partnerships to support the development of therapeutics in areas including neuroscience, oncology, metabolic diseases, infectious diseases, immunology, and rare diseases. Its business model is centered on integrated drug discovery services, platform technologies, milestone payments, licensing revenue, and long-term strategic alliances with global pharmaceutical companies.

The company traces its origins to 1993 as a technology-focused drug discovery business in Hamburg, Germany. Over time, Evotec expanded through acquisitions, platform development, and strategic partnerships, evolving into a diversified discovery and development partner with global operations. A key aspect of its positioning is its “shared R&D” model, under which Evotec collaborates with partners to reduce drug development risk and accelerate innovation using scalable data-driven discovery platforms, induced pluripotent stem cell technologies, and biologics capabilities.

Business Operations

Evotec organizes its activities primarily through the segments Shared R&D and Just – Evotec Biologics. The Shared R&D segment provides integrated drug discovery and development services, including medicinal chemistry, screening, translational biology, pharmacology, and data-driven research platforms. Revenue is generated through fee-for-service contracts, research collaborations, milestone payments, and royalty participation tied to partnered programs. The Just – Evotec Biologics segment focuses on biologics development and manufacturing, including antibody and protein therapeutics, leveraging continuous manufacturing technologies and AI-enabled process optimization.

The company maintains operations across Europe and North America, with research and production facilities in Germany, France, Italy, the United Kingdom, and the United States. Evotec controls a broad portfolio of proprietary technologies, including stem cell platforms, precision medicine capabilities, and biologics manufacturing systems. Strategic partnerships have included collaborations with major pharmaceutical companies such as Bristol Myers Squibb, Bayer, Novo Nordisk, and Takeda. Key subsidiaries and operating entities include Just – Evotec Biologics, Cyprotex, and Aptuit, which expanded the company’s drug discovery, ADME-tox, and development capabilities.

Strategic Position & Investments

Evotec’s strategic direction has focused on expanding integrated drug discovery capabilities, scaling biologics manufacturing, and increasing participation in long-term revenue-sharing partnerships. The company has invested heavily in artificial intelligence-enabled drug discovery, precision medicine platforms, and induced pluripotent stem cell technologies to strengthen its position in translational research. Its strategy also includes co-owned pipeline programs that may generate downstream milestone and royalty revenues in addition to traditional service income.

Major acquisitions have played a central role in Evotec’s growth. The acquisitions of Aptuit Holdings, Cyprotex, and Just Biotherapeutics materially expanded the company’s development, toxicology, and biologics manufacturing capabilities. Through Just – Evotec Biologics, the company has increased investment in continuous biologics manufacturing infrastructure in the United States and Europe. Evotec has also participated in public-private partnerships and infectious disease initiatives, including collaborations involving antimicrobial resistance and pandemic preparedness research.

Geographic Footprint

Evotec is headquartered in Hamburg, Germany, and maintains a broad international operational footprint across Europe and North America. The company operates research, development, and manufacturing facilities in countries including Germany, France, Italy, the United Kingdom, and the United States. Its biologics manufacturing activities have expanded significantly in the U.S., particularly through facilities associated with Just – Evotec Biologics in Seattle and additional manufacturing investments.

The company serves global pharmaceutical and biotechnology clients and maintains collaborative relationships across multiple international markets. Its operational presence enables access to European and U.S. biotech ecosystems, academic research institutions, and pharmaceutical partners. Evotec’s international footprint also supports diversified revenue generation through cross-border research programs, manufacturing agreements, and strategic alliances with multinational healthcare companies.

Leadership & Governance

Evotec operates under a management and supervisory board structure common among German public companies. The company’s leadership has emphasized long-term scientific collaboration, platform scalability, and integrated discovery-to-manufacturing capabilities. Following leadership transitions in recent years, Evotec has continued focusing on operational efficiency, biologics expansion, and strengthening profitability alongside research innovation.

Key executives and leaders include:

• Christian Wojczewski – Chief Executive Officer
• Enno Spillner – Chief Financial Officer
• Cord Dohrmann – Chief Scientific Officer
• Antoine Papiernik – Chairman of the Supervisory Board
• Werner Lanthaler – Former Chief Executive Officer and key architect of the company’s long-term strategic expansion

Public disclosures, including SEC filings, annual reports, earnings releases, and investor presentations, consistently identify Evotec’s strategic emphasis on collaborative drug discovery, technology-enabled research platforms, and biologics manufacturing expansion. Some leadership and organizational details have changed during recent restructuring periods; where reporting differed across public disclosures, data was cross-checked against the most recent company filings and investor communications available.